Get the Stockscreener App
3.72
0.27%
0.01
Collplant Biotechnologies Ltd stock is traded at $3.72, with a volume of 18,066.
It is up +0.27% in the last 24 hours and down -22.63% over the past month.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
See More
Previous Close:
$3.71
Open:
$3.7384
24h Volume:
18,066
Relative Volume:
2.05
Market Cap:
$42.84M
Revenue:
$10.96M
Net Income/Loss:
$-7.02M
P/E Ratio:
-5.9048
EPS:
-0.63
Net Cash Flow:
$-3.72M
1W Performance:
-5.10%
1M Performance:
-22.63%
6M Performance:
-37.48%
1Y Performance:
-33.81%
1-Day Range:
$3.70
$3.75
1-Week Range:
$3.64
$3.99
52-Week Range:
$3.64
$6.99
Collplant Biotechnologies Ltd Stock (CLGN) Company Profile
Name
Collplant Biotechnologies Ltd
Sector
Industry
Phone
-
Address
-
Collplant Biotechnologies Ltd Stock (CLGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-23 | Initiated | Alliance Global Partners | Buy |
Collplant Biotechnologies Ltd Stock (CLGN) Latest News
Collplant stock hits 52-week low at $3.75 amid market challenges - Investing.com Australia
EF Hutton Initiates Coverage of CollPlant Biotechnologies (CLGN) with Buy Recommendation - MSN
Collplant stock hits 52-week low at $4.05 amid market challenges - Investing.com India
Collplant stock hits 52-week low at $4.05 amid market challenges By Investing.com - Investing.com South Africa
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Update - Defense World
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Up 5.3% in September - MarketBeat
Benjamin F. Edwards & Company Inc. Sells 10,690 Shares of CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) - Defense World
CollPlant Shareholders Approve Key Proposals - TipRanks
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Sees Large Growth in Short Interest - MarketBeat
CollPlant (CLGN), Stratasys Initiate Study for Breast Implants - MSN
CollPlant and Stratasys Launch Pre-clinical Trial for Regenerative 3D-Printed Breast Implants - 3DPrint.com
The Stratasys’ Origin® printer to be tested for CollPlant’s 3D-printed breast implants - 3d adept media
HC Wainwright Weighs in on CollPlant Biotechnologies Ltd.'s Q3 2024 Earnings (NASDAQ:CLGN) - MarketBeat
Head-To-Head Analysis: Envoy Medical (NASDAQ:COCH) and CollPlant Biotechnologies (NASDAQ:CLGN) - Defense World
HC Wainwright Weighs in on CollPlant Biotechnologies Ltd.’s Q3 2024 Earnings (NASDAQ:CLGN) - Defense World
FY2027 EPS Estimates for CollPlant Biotechnologies Ltd. Reduced by HC Wainwright (NASDAQ:CLGN) - MarketBeat
HC Wainwright Research Analysts Cut Earnings Estimates for CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) - Defense World
Global Tooth Regeneration Market Size To Worth USD 8.20 Billion By 2033 | CAGR Of 6.18% - GlobeNewswire Inc.
CollPlant Schedules Shareholder Meeting - Investing.com India
CollPlant Schedules Shareholder Meeting By Investing.com - Investing.com Australia
Cracking The Code: Understanding Analyst Reviews For CollPlant Biotechnologies - Benzinga
CollPlant Biotechnologies’ (CLGN) Buy Rating Reaffirmed at HC Wainwright - Defense World
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: CollPlant Biotechnologies reports Q2 2024 financials By Investing.com - Investing.com Australia
CollPlant Biotechnologies Ltd (CLGN) Q2 2024 Earnings Call Trans - GuruFocus.com
Q2 2024 Collplant Biotechnologies Ltd Earnings Call Transcript - GuruFocus.com
CollPlant Announces Upcoming Shareholder Meeting - TipRanks
Collplant stock hits 52-week low at $4.1 amid market challenges - Investing.com
Even after rising 10% this past week, CollPlant Biotechnologies (NASDAQ:CLGN) shareholders are still down 71% over the past three years - Yahoo Finance
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Nasdaq
We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow - Simply Wall St
CollPlant and Stratasys launch pre-clinical study for 3D implants - Investing.com India
CollPlant Biotechnologies (FRA:CPT) Earnings per Share (Dil - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Cash Flow for Lease Fin - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Market Cap : €48.54 Mil (As of Aug. 19, 2024) - GuruFocus.com
CollPlant and Stratasys announce pre-clinical study for regenerative breast implants - Med-Tech Innovation
Stratasys and CollPlant commence pre-clinical study for 3D printed regenerative breast implants - TCT Magazine
CollPlant and Stratasys Announce Pre-clinical Study for Regenerative Commercial-Sized Breast Implants - Lelezard
CollPlant Biotechnologies (FRA:CPT) Cash Flow from Financin - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Cash-to-Debt : 7.69 (As of Mar. 2024) - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Machinery, Furniture, E - GuruFocus.com
CLGN (CollPlant Biotechnologies) Debt-to-Revenue : 7.70 (As of Mar. 2024) - GuruFocus.com
CLGN (CollPlant Biotechnologies) EV-to-Revenue : 3.11 (As of Aug. 18, 2024) - GuruFocus.com
CLGN (CollPlant Biotechnologies) 14-Day RSI : 48.58 (As of Aug. 18, 2024) - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Long-Term Debt & Capita - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Earnings Yield % : N/A% (As of Aug. 17, 2024) - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Accounts Receivable : €0.08 Mil (As of Mar. 2024) - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Change In Receivables : €0.34 Mil (TTM As of Mar. 2024) - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Inventory Turnover : 0.80 (As of Mar. 2024) - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Free Cash Flow per Shar - GuruFocus.com
CollPlant Biotechnologies (FRA:CPT) Preferred Stock : €0.00 Mil (As of Mar. 2024) - GuruFocus.com
Collplant Biotechnologies Ltd Stock (CLGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):